Business Wire

MCR Acquires Cloud-Based Hotel Management Platform Optii

7.12.2021 17:00:00 EET | Business Wire | Press release

Share

MCR, the 4th-largest hotel owner-operator in the United States and one of Fast Company’s 10 Most Innovative Travel Companies of 2020, has acquired Optii, the only predictive, cloud-based technology for improved hotel operations.

Optii will continue to be a standalone company with its existing management team of CEO Katherine Grass, Founder and CSO Soenke Weiss and CRO Deborah Pevenstein.

MCR’s portfolio of 140 branded and independent hotels will be arms-length customers of Optii, which will continue to offer its product to forward-thinking hotel companies. No data will be shared with MCR. MCR will mobilize its 4,000 hotel team members — who will utilize Optii for 20,000 guestrooms per day — to push for innovative product enhancements.

Stayntouch property management system software, another standalone company owned by MCR, will integrate with Optii.

A data-driven platform powered by artificial intelligence, Optii has revolutionized housekeeping technology, optimizing labor and cleaning sequences for faster turnaround times and reduced costs. With its Service and Chat products, Optii streamlines internal communication, allowing managers to auto-assign and track jobs and guest requests in real time, eliminating calls by 95%. The user-friendly mobile and tablet interface can be accessed anywhere, whether on or off property.

Used by hotels to clean more than 10 million guestrooms globally, Optii has experienced stratospheric growth in the past year as hoteliers seek to increase housekeeping productivity while committing to Covid-19 protocols and facing labor shortages.

Fully configurable, the platform connects to many property management systems and is a best-in-class solution for hotels of all sizes, from 50-room boutique properties to 3,000-room casinos. Unlike any other hotel technology, remote onboarding is led by the experts — former executive housekeepers. The software’s artificial intelligence gets smarter over time — around week four, the technology peaks in providing operational efficiencies.

Optii has an aggressive expansion strategy that includes the imminent introduction of a Preventative Maintenance product.

Katherine Grass, CEO of Optii, says, “We are honored to have been selected by MCR to join their portfolio of companies. This acquisition will significantly boost our ability to provide hotels around the world with the technology they need to succeed in today’s operating environment. More and more hotels are realizing that investing in the right technology at this unique time can be a key lever for success. This is a huge growth opportunity for our company to continue momentum in the United States and Europe as well as to further develop our leadership position in Asia.”

Adds Tyler Morse, Chairman and CEO of MCR, “Innovation is a core value of MCR and the acquisition of Optii forwards our mission. At our 140 hotels, we have used every housekeeping technology on the market — and Optii is simply the best. MCR’s investment in Optii will expand its reach globally and provide the company with the resources to continue introducing cutting-edge technology to the hotel industry.”

About Optii Solutions

Optii, headquartered in Austin, Texas, and with offices in New York, London and Brisbane, is a hotel operations solution that leverages smarter technologies such as artificial intelligence, analytics, messaging and mobility to improve the efficiency and effectiveness of hotel operations teams. Optii operates in real time and allows hotels to streamline operations, reduce costs and enhance the guest experience in proven and tangible ways, without requiring capital expenditure and complex integrations. Optii is used by hotels around the world, including the Venetian Macau, part of Las Vegas Sands, La Cantera Resort & Spa and The Don Cesar in the United States, Okada Manilla Resort & Casino, Doma Hotels, Marriott, IHG and more. For further information about Optii, please visit optiisolutions.com.

About MCR

  • 4th-largest hotel owner-operator in the United States
  • $4.0 billion portfolio of 140 premium-branded hotels
  • MCR operates 8 Marriott brands, 6 Hilton brands and a number of unflagged independent hotels
  • 20,000 guestrooms across 34 states and 84 cities
  • Founded in 2006
  • Offices in New York City, Dallas, Chicago and Richmond, Virginia
  • 4,000 team members across the country
  • Three-time recipient of the Marriott Partnership Circle Award , the highest honor Marriott presents to its owner and franchise partners
  • Recipient of the Hilton Legacy Award for Top Performer
  • For the TWA Hotel at New York’s JFK Airport, MCR won the Development of the Year (Full Service) Award at The Americas Lodging Investment Summit (ALIS) , the Urban Land Institute New York Excellence in Hotel Development Award and the American Institute of Architects national Architecture Award, the highest honor given by the AIA
  • Named one of Fast Company’s 10 Most Innovative Travel Companies of 2020
  • For more information, please visit mcrhotels.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Ellie Box: ebox@fireoth.com, +44 7974 791119
Sarah Mulder: smulder@fireoth.com, +44 7720401466

info@mcrhotels.com
(203) 682-8277

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye